Perspectives and unmet needs in polymyalgia rheumatica. Providing the fundamental framework for the development of new treatment regimes in polymyalgia rheumatica

Submitted: 25 August 2017
Accepted: 3 November 2017
Published: 27 March 2018
Abstract Views: 1917
PDF: 1510
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Polymyalgia rheumatica is effectively treated with glucocorticoids. However, glucocorticoid treatment can cause numerous and potentially serious side effects. Therefore, lowest effective dose and shortest duration to control disease is aimed for and glucocorticoid-sparing treatments are needed. Nevertheless, development of treatment regimens in PMR has been hampered by the lack of reliable classification criteria and evidence-based outcome measures. In this editorial, we discuss the need for valid classification criteria in PMR, the strengths and limitations of the ACR/EULAR 2012 provisional classification criteria for PMR and the need of validation and possible refining of the criteria.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

B.D. Nielsen, Department of Rheumatology and Department of Clinical Medicine, Aarhus University Hospital
Department of Rheumatology and Department of Clinical Medicine, MD PhD fellow
B. Dasgupta, Rheumatology Department, Southend University Hospital, Westcliff-on-sea
Rheumatology Department, Professor

How to Cite

Nielsen, B., & Dasgupta, B. (2018). Perspectives and unmet needs in polymyalgia rheumatica. Providing the fundamental framework for the development of new treatment regimes in polymyalgia rheumatica. Reumatismo, 70(1), 1–9. https://doi.org/10.4081/reumatismo.2018.1070